SSRI and Buprenorphine

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

147 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-12-31

Study Completion Date

2009-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to test whether treatment of depressive symptoms using escitalopram improves adherence to Buprenorphine and reduces symptoms of depression for individuals receiving Buprenorphine through their medical provider.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects Of Antidepressants On Sexual Functioning In Adults

NCT00051272

Major Depressive Disorder (MDD)

COMPLETED PHASE3

Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder

NCT02191397

Depressive Disorder, Major

COMPLETED PHASE3

Are Two Antidepressants a Good Initial Treatment for Depression?

NCT00296712

Major Depression Dysthymia Depression NOS

COMPLETED PHASE4

Does Dual Therapy Hasten Antidepressant Response?

NCT00519428

Major Depressive Disorder

COMPLETED PHASE4

Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits

NCT04352101

Major Depression

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants interested in receiving Buprenorphine will be offered the opportunity to enroll in this study. Enrolled study participants will complete interviews at baseline and again every two weeks for a total of 8 interviews over 3 months. In this double-blind randomized controlled trial, participants will either receive a placebo or escitalopram (10mg). All participants will also be followed by their Buprenorphine clinic medical provider. Questions during the face-to-face interviews will assess mood, drug craving, pain, sleep, medication adherence and drug-related experiences. Comparison(s): Participants randomized into the medication component of the study as compared to participants randomized into the placebo component of the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Opiate Dependence Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

placebo

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

placebo capsule/day for 3 months

escitalopram

Group Type ACTIVE_COMPARATOR

escitalopram

Intervention Type DRUG

10mg escitalopram/day for 3 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

escitalopram

10mg escitalopram/day for 3 months

Intervention Type DRUG

placebo

placebo capsule/day for 3 months

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* opiate dependence
* Ham-D \> 14

Exclusion Criteria

* no psychiatric contraindications to using escitalopram
* no medical contraindications to using escitalopram
* methadone dose \< 30
* no current SSRI use

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes